Sanofi Ventures

Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases

Develops programmable epigenetic medicines to treat genetic diseases like FSHD

AI-driven platform that simulates clinical trials to predict outcomes before patient enrollment

Develops lead-212 targeted alpha therapies to treat cancer

Developing transformative, best-in-class neuropsychiatric therapies

Developing next-generation biologics for severe immunological and inflammatory diseases